Exelon Patch, Extended Release
Product Images NDC 66758-142

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Exelon (NDC 66758-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

13.3mgcarton (13.3mgcarton.jpg)

This is a description for Exelon Patch, a transdermal system delivering 13.3 mg of rivastigmine over 24 hours. It is indicated for transdermal use only.*

FDA Label Image

4.6mgcarton (4.6mgcarton)

This is a set of instructions for using the Exelon Patch, a rivastigmine transdermal system. The user is guided to remove the old patch every 24 hours and apply a new one by folding and safely discarding the used patch. The text also provides contact information for more details and specifies that each system delivers 4.6 mg/24 hours for transdermal use only.*

FDA Label Image

9.5mgcarton (9.5mgcarton)

This is information about Exelon Patch, a rivastigmine transdermal system. It is used to deliver 9.5 mg of medication every 24 hours through the skin. The patch needs to be changed every 24 hours by removing the old one and applying a new one. Instructions are provided on how to discard the patch safely and wash hands with soap and water. For more details, visit the website www.sandoz.com or call 1-800-525-8747. Each package contains 30 systems.*

FDA Label Image

Rivastigmine Chemical Structure (Exelon Patch 01)

FDA Label Image

Figure 1: Cross Section Of The Exelon Patch (Exelon Patch 02)

FDA Label Image

Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-hour Patch Application (Exelon Patch 03)

This description provides information on the levels of Rivastigmine in the given samples at different dosages. The data displays the concentrations of Rivastigmine in nanograms per milliliter for three groups: 133 mg/24 hours with n=19, 9.5 mg/24 hours with n=22, and 4.6 mg/24 hours with n=22. The values suggest a comparison between the dosage levels and their corresponding concentrations of Rivastigmine.*

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Adas-cog Score For Patients Observed At Each Time Point (Exelon Patch 04)

FDA Label Image

Figure 4: Distribution Of Adcs-cgic Scores For Patients Completing The Study (Exelon Patch 05)

FDA Label Image

Cut The Pouch Along The Dotted Line And Remove The Patch. (Exelon Patch 07)

This text appears to be a list of body parts where a procedure or examination may be performed. It includes options such as left or right upper arm, left or right side of chest, side, left or right upper back, and left or right lower back. This list might be used in a medical context for selecting the specific area on which a particular action needs to be performed.*

FDA Label Image

Put The Sticky Side Of The Patch On The Upper Or Lower Back, Upper Arm Or Chest And Then Peel Off The Second Side Of The Protective Liner. (Exelon Patch 09)

This text is not readable.*

FDA Label Image

Press The Patch Firmly In Place With The Hand To Make Sure That The Edges Stick Well. (Exelon Patch 0a)

FDA Label Image

Figure 5 Time Course Of The Change From Double-blind Baseline In Adcs-iadl Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0d)

This text appears to be a brief summary of a clinical study comparing two different doses of a medication called "Evelon Patch," specifically the 13.3 mg dose versus the 95 mg dose. The study appears to have assessed changes in ADCS-IADL scores from baseline over the course of treatment. It also mentions "Clinical improvement" and "Clinical decline" which may indicate the study evaluated the clinical outcomes associated with the two doses of the patch.*

FDA Label Image

Figure 6 Time Course Of The Change From Double-blind Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0e)

FDA Label Image

Figure 7 Time Course Of The Change From Baseline In Sib Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Exelon Patch 0g)

The provided text includes information on clinical statistics related to improvement seen in patients undergoing treatment for eye decline with Rivastigmine patches. It mentions LS mean difference in improvement, confidence intervals, and statistical significance levels. The data is derived from an analysis of covariance model adjusted for baseline values. The use of different sizes of Rivastigmine patches is also indicated.*

FDA Label Image

Figure 8 Time Course Of The Change From Baseline In Adcs-adl-siv Score For Patients Observed At Each Time Point (modified Full Analysis Set – Locf) (Exelon Patch 0h)

FDA Label Image

Figure F (Exelon Patch 0i)

FDA Label Image

Figure G (Exelon Patch 0j)

FDA Label Image

Figurea (Figurea)

This is a description for Pouch Exelon Patch Protective Liners that contain rivastigmine for transdermal use. The patch delivers medication through the skin. Each pouch contains 1 system with adhesive and protective liners.*

FDA Label Image

Figurec (Figurec)

FDA Label Image

Figureh (Figureh)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.